Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study.
Devin AbrahamiAntonios DourosHui YinOriana Hy YuJean-Luc FaillieFrançois MontastrucRobert W PlattNathaniel BouganimLaurent AzoulayPublished in: BMJ (Clinical research ed.) (2018)
Compared with use of other second or third line antidiabetic drugs, use of DPP-4 inhibitors, and possibly GLP-1 receptor agonists, might be associated with an increased risk of cholangiocarcinoma in adults with type 2 diabetes.
Keyphrases